<DOC>
	<DOCNO>NCT01498822</DOCNO>
	<brief_summary>To evaluate long term effectiveness Levetiracetam ( LEV ) monotherapy Treatment Failure Rate subject newly diagnose partial onset seizure without secondary generalized seizure , compare Oxcarbazepine ( OXC ) monotherapy 50 week first dose</brief_summary>
	<brief_title>Levetiracetam Versus Oxcarbazepine Monotherapy Evaluate Efficacy Safety Subjects With Newly Recently Diagnosed Partial Epilepsy</brief_title>
	<detailed_description>The study duration consist follow period : - Baseline period one week : Week -1 - Titration period two week : Week 0 Week 1 - Treatment period 48 week : Week 2 Week 50</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Oxcarbazepine</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Male female subject 16 80 year , inclusive . Vulnerable subject ( e.g. , 20 year subject learn disability judge capable understand ) may include legally permit ethically accepted Subjects newly recently diagnose epilepsy experience unprovoked partial seizure ( IA , IB , IC clear focal origin ) , classifiable accord International Classification Epileptic seizure ( 1981 ) . Undiscriminated subject IC IIE could include Subjects least 2 unprovoked seizure separate minimum 48 hour year precede randomization least 1 unprovoked seizure 6 month precede randomization Subjects document evidence EEG brain MRI CT scan medical record perform within 1 year prior Visit 1 ( V1 ) Subjects treatment antiepileptic drug 6 month precede study . The treatment acute seizure control acceptable maximum 2 week duration treatment stop least 1 week V1 . For Phenobarbital Phenobarbital derivative , minimum 4 week washout request V1 Subject current previous diagnosis pseudoseizures , conversion disorder , nonepileptic ictal event could confuse seizure Subject take 1 follow medication regular basis within 28 day prior Visit 1 : neuroleptic , monoamine oxidase ( MAO ) inhibitor narcotic analgesic Subject take immunosuppressant within 28 day prior Visit 1 Subject history suicide attempt , receive professional counseling suicidal ideation , currently experience active suicidal ideation Subject seizure disorder characterize primarily isolate aura ( ie , simple partial seizure without observable motor sign ) Subject suffer seizure partial ( IA , IB , IC , clear focal origin ) seizures Subject history status epilepticus within last 3month period prior Visit 1 Subject seizure uncountable due clustering ( ie , episode last less 30 minute several seizure occur frequency initiation completion individual seizure distinguish ) 12week period prior Visit 1 and/or Screening Period Body weight low 40 kg ( &lt; 40 kg )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Levetiracetam</keyword>
	<keyword>Oxcarbazepine</keyword>
	<keyword>treatment failure</keyword>
	<keyword>partial epilepsy</keyword>
</DOC>